Table 1.
Phenotypic and genotypic features of the isolates from this study
| Sample | Isolation site | Isolation date | Susceptible profile | Resistome | Virulome | ||||
|---|---|---|---|---|---|---|---|---|---|
| Vancomycin MIC µg/mL | Teicoplanin MIC µg/mL | Aminoglycoside | Glycopeptide | MLS | Adherence | Colonization | |||
| Ef1 | Blood | 2007 | 128 | 16 | aph(3')-III, ant(6)-Ia |
vanH-A, vanA, vanX-A, vanZ-A, vanY-A, vanR-A, vanS-A |
msr(C), erm(B) | acm, efaAfm, esp, asa1 | gelE |
| Ef2 | Blood | 2006 | 128 | 8 | aph(3')-III, ant(6)-Ia |
vanH-A, vanA, vanX-A, vanZ-A, vanR-A, vanS-A |
msr(C), erm(B), lnu(B) | acm, efaAfm, esp, asa1 | gelE |
| Ef3 | Rectal swab | 2013 | 256 | 16 | aph(3')-III, ant(6)-Ia |
vanH-A, vanA, vanX-A, vanZ-A, vanY-A, vanR-A, vanS-A, |
msr(C), erm(B) | acm, efaAfm, esp, asa1 | gelE |
| Ef4 | Feces | 2013 | 128 | 16 | aph(3')-III, aac(6')-aph(2'') |
vanH-A, vanA, vanX-A, vanZ-A, vanY-A, vanR-A, vanS-A |
msr(C), erm(B), lnu(B) | acm, efaAfm, esp, asa1 | - |
| Ef5 | Feces | 2013 | 128 | 8 | aph(3')-III, ant(6)-Ia | vanH-A, vanA, vanX-A,vanR-A, vanS-A | msr(C), erm(B) | acm, efaAfm, esp, asa1 | - |
| Ef6 | Feces | 2014 | 128 | 16 | aph(3')-III, ant(6)-Ia |
vanH-A, vanA, vanX-A, vanZ-A, vanY-A, vanR-A, vanS-A |
msr(C), erm(B) | acm, efaAfm, esp | - |
| Ef7 | Nasal swab | 2014 | 128 | 16 | aph(3')-III |
vanH-A, vanA, vanX-A, vanZ-A, vanY-A, vanR-A, vanS-A |
msr(C), erm(B) | acm, efaAfm | - |
| Ef8 | Feces | 2014 | 256 | 16 | aph(3')-III, ant(6)-Ia |
vanH-A, vanA, vanX-A, vanZ-A, vanY-A, vanR-A, vanS-A |
msr(C), erm(B) | acm, efaAfm, esp | - |
| Ef9 | Feces | 2014 | 128 | 16 | aph(3')-III, ant(6)-Ia |
vanH-A, vanA, vanX-A, vanZ-A, vanY-A, vanR-A, vanS-A |
msr(C), erm(B) | acm, efaAfm, esp | - |
MIC minimum inhibitory concentration, MLS macrolide, lincosamide, and streptogramin